Abstract Titles
Skip to Late-Breaking Abstracts »
All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Onsite Posters
Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.
ePosters
ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.
| # | Type | Title | Authors | Category | Keywords | |
|---|---|---|---|---|---|---|
| 390 | Poster Presentation | A Global, Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials | Melissa L. Johnson, MD; Adrian Sacher; Marcus O. Butler; Hassane Zarour; Jeffrey Weber; Edward B. Garon; David P. Carbone, MD, PhD; Arindam Dhar; Cristina H. Messina; Roma Patel; Kristin Blouch; Axel Hoos; Anne-Marie Martin | Clinical Trials In Progress | Biomarkers;Clinical study;Gene expression;Immune contexture;Tumor microenvironment | |
| 391 | Poster Presentation | Biomarker correlates of response in patients with advanced Myxoid/Round Cell Liposarcoma (MRCLS) treated with NY-ESO-1 TCR T cells (Letetresgene autoleucel) | Gurpreet S. Kapoor, PhD; Stefan Zajic; Sunil Suchindran; Jaegil Kim; Ioanna S. Eleftheriadou; Anne Huff; Michael Nathenson; Mihaela Druta; Brian A. Van Tine, MD, PhD; Neeta Somaiah, MD, MBBS; David A. Liebner, MD; Scott Schuetze; Sandra D’Angelo | Clinical Trials In Progress | Adoptive immunotherapy;Biomarkers;Chemokine;Cytokine;Gene expression;Immune monitoring;Pediatric tumors;Solid tumors;T cell;Targeted therapy | |
| 392 | Poster Presentation | A Phase 1a/b Study of IK-175, an Oral AHR Inhibitor, Alone and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | Meredith McKean, MD; Jason J. Luke; Nehal J. Lakhani, MD; Babar Bashir, MD, MS; David H. Aggen, MD, PhD; Alan Tan, MD; Katherine Kacena, PhD; Lei Wang, PhD; Marissa Timothy, MS; Sergio L. Santillana, MD, MSc, MBA | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 393 | Poster Presentation | A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers | Samuel J. Klempner, MD; John H. Strickler, MD; Lindsey Gourley; Celine Jacquemont; Vinona Bhatia; Naomi Hunder; Valerie Odegard, PhD; Sarina A. Piha-Paul, MD | Clinical Trials In Progress | Antibody;Biomarkers;Cytokine;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Neoantigens;NK/NKT cell;T cell;TLR | |
| 395 | Poster Presentation | Detection of viral antigen and immune activation after intra-tumor injection of CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma | Francesca Barone, MD, PhD; Sean e. Lawler, PhD; Laura K. Aguilar, MD, PhD; Jessica E. Dwyer; Brian Guzik, PhD; Isaac H. Soloman; Hiroshi Nakashima, PhD; Daniel Triggs, NP; Abigail Tianai Zhang; Yu Zeng, PhD; Jared Woods, MD, PhD; James Grant; David A. Reardon, MD; Patrick Y. Wen, MD; Eudocia Quant Lee, MD, MPH; Keith L. Ligon, MD, PhD; William Pisano; Scott J. Rodig, MD, PhD; Mario Suva, MD, PhD; Kai W. Wucherpfennig, MD, PhD; Sascha Marx, MD; Simon Gritsch, MD, PhD; Nathan D. Mathewson, PhD; Mariano Severgnini, MSc; Anita Giobbie-Hurder, MS; David Krisky, MD, PhD; Estuardo Aguilar-Cordova, MD, inf., PhD; Paul P. Tak, MD, PhD, FMedSci; E. Antonio Chiocca, MD, PhD | Clinical Trials In Progress | Chemokine;Clinical study;Clinical trial;Cytokine;Immune monitoring;Inflammation;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 396 | Poster Presentation | NT-I7, a long-acting interleukin-7, promotes expansion of CD8 T cells and NK cells and immune activation in patients with newly diagnosed high-grade gliomas after chemoradiation | Alice Y. Zhou, MD, PhD; Michael P. Rettig, PhD; Jennifer A. Foltz, PhD; Jingqin Luo, PhD; Omar H. Butt, MD, PhD; Chai Avvaru; Ruth GN. Katumba; Albert H. Kim, MD, PhD; Gavin P. Dunn, MD, PhD; Christopher D. Abraham, MD; Se Hwan Yang, PhD; Jean Fan, MD, MSc; Byung Ha Lee, PhD; NgocDiep Le, MD, PhD; George Ansstas, MD; Tanner M. Johanns, MD, PhD; Jiayi Huang, MD; Milan G. Chheda, MD; Todd A. Fehniger, MD, PhD; Jian L. Campian, MD, PhD | Clinical Trials In Progress | Clinical study;Clinical trial;Immune adjuvant;Immune monitoring | |
| 397 | Poster Presentation | A phase I/II trial of intracerebroventricular 177Lu DTPA omburtamab radioimmunotherapy for leptomeningeal metastasis from solid tumors | Elena Pentsova; Maria Düring; Charlotte Lybek Lind; John Rømer Nielsen | Clinical Trials In Progress | Antibody;Clinical study;Clinical trial;Radiotherapy;Targeted therapy | |
| 398 | Poster Presentation | neoIRX: a phase II trial of locoregional cytokine therapy to promote immunologic priming and clinical response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC) | Katherine Sanchez, MD; Alison K. Conlin, MD; Parvin Peddi, MD; Sasha E. Stanton, MD; Janet Ruzich, MD; Kelly Perlewitz, MD; Yaping Wu, MD; Nicole Moxon, RN, BSN, OCN; Staci Mellinger, RN; Zhaoyu Sun, Ph.D.; William L. Redmond, Ph.D.; David B. Page, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial | |
| 399 | Poster Presentation | A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer | David B. Page, MD; Krystle L. Collins, MD; Brie M. Chun, MD; Zhaoyu Sun, Ph.D.; Yoshinobu Koguchi, MD, PhD; William L. Redmond, Ph.D.; Maritza Martel, MD; Yaping Wu, MD; Nicole Moxon, RN, BSN, OCN; Staci Mellinger, RN; Walter J. Urba, MD, PhD; Ayca Gucalp, MD; Tiffany A. Traina, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Immune adjuvant;Solid tumors;T cell;Tumor microenvironment | |
| 400 | Poster Presentation | Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-therapy drug product | Marco Purbhoo, PhD; Burcu Yigit, PhD; Darrian Moskowitz; Min Lim; Irina Shapiro; Ayat Alsaraby; Xavier Michelet, PhD; Marc A. Van Dijk, PhD | Clinical Trials In Progress | Adoptive immunotherapy;Clinical trial;COVID and Immunotherapy;Leukemia/Lymphoma;NK/NKT cell;T cell lineages | |
| 402 | Poster Presentation | Pegasus GI, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with anti-cancer agents of participants with advanced and metastatic gastrointestinal cancer | William HARRIS, MD; Adyb BAAKILI, MD; Yoon-Koo KANG, MD; Brigitte DEMERS, MD; Fatima-Zohra Menas, MD; Alice GOSSELIN; Giovanni Abbadessa, MD; Eric Van Cutsem, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;NK/NKT cell;Solid tumors;T cell | |
| 403 | Poster Presentation | Correlative analysis of blood and biopsy samples from a clinical trial of Hsp90 inhibition in combination with pembrolizumab reveals increased intratumoral myeloid cell accumulation after treatment | Cameron J. Herting, PhD; Yuchen Zhang; Deon B. Doxie, PhD; Michael B. Ware, PhD; Olatunji B. Alese, MD; Christina Wu, MD; Mehmet Akce; Mohammad Y. Zaidi, MD, MS; Amanda N. Ruggieri, MS; Madhav Dhodapkar, MD; Kavita M. Dhodapkar, MD; Juan M. Sarmiento, MD; Rafi Ahmed, PhD; Shishir K. Maithel, MD; Bassel El-Rayes, MD; Gregory B. Lesinski, PhD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemokine;Clinical trial;Immune monitoring;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 404 | Poster Presentation | Initial Biomarker and Clinical Data of a Phase 2a Study of NT-I7, a Long-Acting Interleukin-7, plus Pembrolizumab: Cohort of Subjects with Checkpoint Inhibitor-naïve Advanced MSS-Colorectal Cancer | Richard D. Kim, MD; Minal A. Barve, MD; Hirva M. Mamdani, MD; Melissa L. Johnson, MD; Byung Ha Lee, PhD; Sara Ferrando-Martinez, PhD; Marya F. Chaney, PhD; Jean Fan, MD, MSc; NgocDiep Le, MD, PhD; Aung Naing, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Cytokine;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 405 | Poster Presentation | Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): a phase Ⅱ, single-arm, exploratory research | Jianqun Ma, MD; Jinfeng Zhang; Yingnan Yang; Dayong Zheng; Xiaoyuan Wang; Hao Liang; Luquan Zhang; Yanzhong Xin; Xiaodong Ling; Chengyuan Fang; Hao Jiang; Hongxue Meng; Wei Zheng | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Surgery | |
| 406 | Poster Presentation | Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: a phase Ⅱ, single-arm, exploratory research | Jianqun Ma, MD; Jinfeng Zhang; Yingnan Yang; Dayong Zheng; Xiaoyuan Wang; Hao Liang; Luquan Zhang; Yanzhong Xin; Xiaodong Ling; Chengyuan Fang; Hao Jiang; Wei Zheng | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy | |
| 407 | Poster Presentation | A Phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients | Anne Flament, MD; Frédéric F. Lehmann, MD; Erik M. Alcantar-Orozco, MD, PhD; Emilie Cerf, PhD; Caroline Lonez, PhD; David E. Gilham, PhD; Charles Morris, MD | Clinical Trials In Progress | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Clinical trial;Solid tumors | |
| 408 | Poster Presentation | Preliminary Biomarker and Clinical Data of a Phase 2a Study of NT-I7, a Long-Acting Interleukin-7, plus Pembrolizumab: Cohort of Subjects with Checkpoint Inhibitor-naïve Advanced Pancreatic Cancer | Aung Naing, MD; Richard D. Kim, MD; Minal A. Barve, MD; Melissa L. Johnson, MD; Byung Ha Lee, PhD; Sara Ferrando-Martinez, PhD; Shubham Pant, MD; Robert A. Wolff, MD; Cara Haymaker, PhD; Marya F. Chaney, PhD; Dae Won Kim, MD; Jean Fan, MD, MSc; NgocDiep Le, MD, PhD; Hirva M. Mamdani, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Cytokine;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 409 | Poster Presentation | Trial in progress: A phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer | Do-Youn Oh, MD, PhD; Min Hee Ryu, MD, PhD; Jun-Eul Hwang, MD, PhD; Jaeyong Cho, MD, PhD; Dae Young Zang, MD, PhD; Sang Cheul Oh, MD, PhD; Jeeyun Lee, MD, PhD; Keun-Wook Lee, MD, PhD; Hyun Cheol Chung, MD, PhD; Byoung Yong Shim, MD, PhD; Michael Chisamore, PhD; William Y. Ho, MD, PhD; Paul D. Rhee, Ph.D.; Ji Yeong Won, PhD; Taewan Kim; Eunhye Baek; SeungJae Baek, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Chemokine;Clinical study;Clinical trial;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment | |
| 410 | Poster Presentation | Phase I Interim Study Results of Nous-209, an Off-the-Shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/ Microsatellite Instability (dMMR/MSI) | Michael J. Overman, MD; Marwan Fakih; Dung T. Le, MD; Anthony F. Shields, MD PhD; Katrina S. Pedersen; Manish A. Shah, MD; Sarbajit Mukherjee, MD, MS; Thea Faivre; Guido Leoni, PhD; Anna Morena D'Alise; Gabriella Cotugno, PhD; Francesca Langone, PhD; Stefania Capone; Maria Rosaria Del Sorbo; Elisa Scarselli; Patricia Delaite, MD | Clinical Trials In Progress | Bioinformatics;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;T cell;Vaccine | |
| 411 | Poster Presentation | INNATE: Immunotherapy during neoadjuvant therapy for rectal cancer to elucidate local and systemic therapeutic responses. | Nina N. Sanford, MD; Eslam Elghonaimy, PhD; Adel Kardosh, MD; Syed A. Kazmi, MD; Javier Salgado Pogacnik, MD; Xiaodong Yang, MD PhD; Robert Timmerman, MD; Todd A. Aguilera, MD, PhD | Clinical Trials In Progress | Antigen presenting cells;Bioinformatics;Chemotherapy;Radiotherapy;Solid tumors;Tumor microenvironment | |
| 412 | Poster Presentation | CAMrelizumab and apatiniB combIned with chemoTherapy (mFOLFOX6) as neoadjuvant therapy for locally advanced rIght-sided colON cancer (AMBITION) | Zhou Tong, master; Sen Lu; Xiaomeng Dai; Xiaobin Cheng; Xuanwen Bao; Xudong Zhu; Xiaofei Cheng; Qihan Fu; Danyang Wang; Hangyu Zhang; Qinsong Sheng; Lulu Liu; Guoliang Zhang; Yi Zheng; Fanlong Liu; Peng Zhao; Wenbin Chen; Weijia Fang, PHD; Xiangmin Xu | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical trial | |
| 413 | Poster Presentation | Toripalimab in combination with concurrent chemoradiation in patients with advanced/metastatic esophageal carcinoma: protocol for a single-arm, prospective, open-label, phase II clinical trial | Lei Wu, M.M.; Yi Wang, M.M.; Gang Wan, M.M.; Jiahua Lv, M.M.; Qifeng Wang, M.D.; Jinyi Lang, M.D.; Tao Li, M.D. | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical trial;Radiotherapy | |
| 414 | Poster Presentation | A randomized phase II study of systemic therapy plus WeiLeShu (WLS) versus systemic therapy alone in patients with metastatic colorectal cancer (mCRC). | Ruyi Zhang; Xiaoxuan Tu, MS; Zhou Tong, master; Hangyu Zhang; Xudong Zhu; Weijia Fang, PHD; Lanfang Yu; Haibo Mou | Clinical Trials In Progress | Chemokine;Chemotherapy;Clinical trial;Inflammation;Microbiome;Monocyte/Macrophage;Solid tumors;Tumor microenvironment | |
| 416 | Poster Presentation | An open-label phase 2 study of 2 doses of the hypoxia-inducible factor (HIF)–2α inhibitor belzutifan for the treatment of advanced clear cell renal cell carcinoma after progression on systemic therapy | Michael B. Atkins, MD; Yanfang Liu; Rodolfo Perini, MD; Ananya Roy; John B. Haanen, MD | Clinical Trials In Progress | Clinical study;Clinical trial;Targeted therapy | |
| 417 | Poster Presentation | Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma | Toni K. Choueiri, MD; Elizabeth R. Plimack, MD MS; Thomas Powles, MBBS, MD, MRCP; Martin Voss, MD; Howard Gurney; Rachel Silverman; Rodolfo Perini, MD; Karla Rodriguez-Lopez; Brian I. Rini, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial | |
| 418 | Poster Presentation | Phase 1b/2 KEYNOTE-365 cohort I: Platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma | Johann S. De Bono, PhD; Neal Shore, MD, FACS; Gero Kramer, MD; Anthony M. Joshua, MBBS, PhD; Xin Tong Li; Christian H. Poehlein, MD; Charles Schloss; Evan Y. Yu, MD | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial | |
| 419 | Poster Presentation | Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F | Gero Kramer, MD; Neal Shore, MD, FACS; Anthony M. Joshua, MBBS, PhD; Xin Tong Li; Christian H. Poehlein, MD; Charles Schloss; Johann S. De Bono, PhD; Evan Y. Yu, MD | Clinical Trials In Progress | Angiogenesis;Checkpoint blockade;Clinical trial | |
| 420 | Poster Presentation | PROSTVAC in combination with Nivolumab enhanced immune cell infiltration in prostate cancer. | Shania A. Bailey, BS; Wiem Lassoued, PhD; Antonios Papanicolau-Sengos, MD; Jennifer L. Marte, MD, MPH; Nikki Williams; amy hankin; michell manu; William Dahut, MD; peter pinto; Fatima Karzai, MD; Ravi A. Madan, MD; Houssein Abdul Sater, MD; James L. Gulley, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 421 | Poster Presentation | A first-in-human (FIH) Phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT | Mark Linch; Zsuzsanna Papai; Istvan Takacs; Esteban Rodrigo Imedio; Marie-Cristine Kühnle; Evelyna Derhovanessian; Isabel Vogler; Stephanie Renken; Philippa Graham; Ugur Sahin; Özlem Türeci | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;RNA;T cell;Tumor antigens;Vaccine | |
| 422 | Poster Presentation | Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma | Tanner S. Miest; Bradley Leibovich; Stephen Bardot; Paul R. Young; Stephen A. Boorjian; Mark Gonzalgo; Loren Herrera-Hernandez; Matthew K. Tollefson; Jeffrey Karnes; Paige Nichols; Tessa Kroeninger; Rachel Graham; Carole Lahana; Monica Reckner; Alysha Newsom; Nandakumar Packiriswamy; Janice Anoka; Kah Whye Peng; Erol Wiegert; Alice Bexon; Shruthi Naik | Clinical Trials In Progress | Clinical trial;Targeted therapy;Vaccine | |
| 423 | Poster Presentation | A Phase 2 Study of Ibrutinib as Neoadjuvant Therapy in Patients with Localized Prostate Cancer | Russell Pachynski, MD; Melissa A. Reimers; Cody Weimholt, MD; Katie Slane, NP; Peter Oppelt, MD; Jason Frankel, MD; Robert Figenshau, MD; Eric Kim, MD; Gerald Andriole, MD; Lawrence Fong, MD | Clinical Trials In Progress | B cell;Clinical study;Clinical trial;Inflammation;Myeloid cells;Surgery;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 424 | Poster Presentation | A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment | Kathryn E. Beckermann, MD, PhD; Nicholas J. Vogelzang, MD; Mao Shifeng; Moshe C. Ornstein; Neil Shah, MD; Hans Hammers, MD, PhD; Matthew T. Campbell, MD; Xin Gao; David F. McDermott, MD; Randy Anderson; Vanessa Esquibel, Director; Eduardo J. Pennella, MD; Reshma Rangwala, MD, PhD; Eric Jonasch, MD | Clinical Trials In Progress | Angiogenesis;Antibody;Chemotherapy;Clinical study;Clinical trial;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 425 | Poster Presentation | Pembrolizumab + vibostolimab in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts G/H | Neal Shore, MD, FACS; Johann S. De Bono, PhD; Gero Kramer, MD; Anthony M. Joshua, MBBS, PhD; Xin Tong Li; Christian H. Poehlein, MD; Charles Schloss; Evan Y. Yu, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial | |
| 426 | Poster Presentation | A phase 3, single-arm study of CG0070 in subjects with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) | Ed M. Uchio, MD; Donald Lamm, MD, FACS; Neal Shore, MD; Paul Anderson, MD; Tran Ben, MD; Ashish M. Kamat, MD; John McAdory, MHA; Melody Keel; Paola Grandi, PhD, MBA; James Burke, MD | Clinical Trials In Progress | Clinical trial | |
| 427 | Poster Presentation | Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study | Jermaine Coward; Sophia Frentzas; Anna Mislang; Bo Gao; Charlotte Lemech, MBBS BSc(med) FRACP MD(res); Xiaoping Jin, PhD; Baiyong Li, Ph.D; Max Wang; Kon Yew Kwek; Yiting Zhou; Yu Xia | Clinical Trials In Progress | Angiogenesis;Antibody;Bispecifics;Checkpoint blockade;Clinical trial;Coinhibition;Immune suppression;Solid tumors | |
| 428 | Poster Presentation | Preliminary Clinical Results of Toripalimab Monotherapy or Combination Therapy for Recurrent or Refractory Gynecologic Cancer | Peng Diao; Qian Peng; Xingbo Luo; Qing Huang; Gaoshu Yan; Yan Tan | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Radiotherapy | |
| 429 | Poster Presentation | Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer | Nehal J. Lakhani, MD; Debra Richardson, MD; Timothy Kristedja, MD; Fatima Rangwala, MD, PhD; Hannah McKay; Louis E. Gonzalez, PhD; Bo Ma, PhD; Erika P. Hamilton, MD; Lini Pandite, MD | Clinical Trials In Progress | Antigen presenting cells;Biomarkers;Bispecifics;Checkpoint blockade;Clinical trial;Costimulation | |
| 430 | Poster Presentation | A phase 1b/II clinical study of AK112, a PD-1/VEGF bispecific antibody, in combination with olaparib in BRCA germline wild-type platinum sensitive recurrent ovarian cancer | Lingying Wu; Guiling Li; Bairong Xia; Rong Li; Jing Wang; Ruifang An; Li Wang; Yunxia Li; Kun Song; Hongying Yang; Yaqing Chen; Yuzhi Li; Huiling Huang; Xiaoping Jin; Baiyong Li, Ph.D; Yu Xia | Clinical Trials In Progress | Angiogenesis;Antibody;Bispecifics;Checkpoint blockade;Clinical trial;Coinhibition;Targeted therapy | |
| 431 | Poster Presentation | First-in-human phase I clinical trial evaluating intraperitoneal administration of MOv19-BBz CAR T cells in patients with alpha folate receptor-expressing recurrent high grade serous ovarian cancer | Payal D. Shah, MD; Richard Shlanksy-Goldberg, MD; Lainie Martin, MD; Gregory Nadolski, MD; Elizabeth Hexner, MD; Susan Shamimi-Noori, MD; Wei-Ting Hwang, Ph.D.; Tina Matlawski, RN; Amanda L. Cervini; Joanne B. Shea, RN; Lauren M. Nelson; Simon F. Lacey, Ph.D.; Gabriela Plesa, MD, Ph.D.; Lester R. Lledo, DNP, RN, CRNP; Karen L. Dengel, BSN, RN; Amy E. Marshall, MPH; Rachel M. Leskowitz, Ph.D.; Lana Kandalaft, Pharm.D.; Mariangela Figini; Silvana Canevari, Ph.D.; George Coukos, MD, Ph.D.; Daniel J. Powell Jr., Ph.D. | Clinical Trials In Progress | Adoptive immunotherapy;CAR T cells;Clinical trial;Solid tumors | |
| 432 | Poster Presentation | Nemvaleukin alfa, a novel engineered IL-2 cytokine, in combination with the anti-PD-1 antibody pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma (ION-01 study) | Brian Gastman, MD; Mac A. Cheever, MD; Steven P. Fling, PhD; Cesar A. Perez, MD; Manish R. Patel, MD; Jessica L. Geiger, MD; Zujun Li, MD; Marshall R. Posner, MD; Conor E. Steuer, MD; Leonard A. D'Amico, PhD; Angela Shaulov Kask, PhD; Yangchun Du, PhD; Derek Matthies, PharmD; Sung Jin Huh, PhD; Yan Wang, PhD; Julie R. Graham, PhD; Laura QM. Chow, MD | Clinical Trials In Progress | Biomarkers;Clinical study;Clinical trial;Cytokine;Immune monitoring;Immune suppression;Immune tolerance;Immune toxicity;Tumor microenvironment | |
| 433 | Poster Presentation | A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04 | Beatriz B. Cirauqui, MD; Ezra EW. Cohen, MD; Bhumsuk Keam, MD, PhD; Jean-Pascal Machiels, MD, PhD; Sjoukje Oosting, MD, PhD; Tim Welliver, MD, PhD; Shanhong Guan, PhD; Feng Jin, PhD; Alison J. Forgie, PhD; Philip S. Fanning, PhD; Katherine Ruffner, MD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Kevin Harrington, PhD, FRCP, FRCR | Clinical Trials In Progress | Antigen presenting cells;Checkpoint blockade;Clinical study;Clinical trial;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor evasion;Tumor microenvironment | |
| 434 | Poster Presentation | Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84) | Elizabeth E. Evans, PhD; Terrence L. Fisher, Jr., PhD; Crystal Mallow, BS; Amber Foster; Ernest S. Smith, PhD; John E. Leonard, MD PhD; Marya F. Chaney, PhD; Maurice Zauderer, PhD | Clinical Trials In Progress | Antibody;Antigen presenting cells;Biomarkers;Checkpoint blockade;Clinical trial;Immune suppression;MDSC;Myeloid cells;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 435 | Poster Presentation | Pegasus HNSCC, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with recurrent/metastatic head and neck squamous cell carcinoma | Robin Meng, MD, PhD; Caroline Even; Lisa Licitra, MD; Chia-Jui Yen, MD, PhD; Myung Ju Ahn, MD; Giovanni Abbadessa, MD; Fatima-Zohra Menas, MD; Miao Zang; George R. Blumenschein, Jr., MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;NK/NKT cell;Solid tumors;T cell | |
| 436 | Poster Presentation | A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy | Haiqiang Mai; haiqiang Mai; Shaojun Lin; Dongping Chen; Xiaozhong Chen; Song Qu; Qin Lin; Ying Luo; Chunhong Hu; Dehua Wu; Tianxin Qin; Feng Jin; Nianyong Chen; Yunxiu Luo; Zhifang Yao; Xiaoping Jin; Baiyong Li, Ph.D; Yu Xia; Rui-Hua Xu | Clinical Trials In Progress | Bispecifics;Checkpoint blockade;Clinical trial;Coinhibition;Solid tumors | |
| 437 | Poster Presentation | A multicentre phase 1b study of NG-641, a novel transgene-armed and tumour-selective adenoviral vector, and pembrolizumab as neoadjuvant treatment for squamous cell carcinoma of the head and neck | Christian Ottensmeier; Mererid Evans; Emma King; Ioannis Karydis; Tom Lillie, MD PhD; David Krige, PhD; Jenny Lee; Matthew R. Thomas, PhD; Kevin Harrington, PhD, FRCP, FRCR | Clinical Trials In Progress | Antibody;Bispecifics;Checkpoint blockade;Clinical trial;Solid tumors;Tumor microenvironment | |
| 438 | Poster Presentation | A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer | Christine H. Chung, MD; A. Dimitrios Colevas, MD; Michael K. Gibson, MD PhD; Douglas R. Adkins, MD; Ammar Sukari, MD; Lori J. Wirth, MD; Barbara A. Burtness, MD; Julie E. Bauman, MD, MPH; Cristina P. Rodriguez, MD; Francis P. Worden, MD; Nabil F. Saba, MD; Bonnie S. Glisson, MD; Lara A. Dunn, MD; Tanguy Y. Seiwert, MD; Laura Agensky; Matteo Levisetti; Reena Lynam; Steven P. Margossian, MD, PhD; Raymond J. Moniz, PhD; Steve N. Quayle, PhD; Kenneth J. Pienta, MD; Sara I. Pai, MD PhD | Clinical Trials In Progress | Adoptive immunotherapy;Checkpoint blockade;Clinical trial;Costimulation;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 439 | Poster Presentation | A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03 | Jong Chul Park, MD; Kevin Harrington, PhD, FRCP, FRCR; Bhumsuk Keam, MD, PhD; Jean-Pascal Machiels, MD, PhD; Sjoukje Oosting, MD, PhD; Tim Welliver, MD, PhD; Shanhong Guan, PhD; Feng Jin, PhD; Alison J. Forgie, PhD; Philip S. Fanning, PhD; Katherine Ruffner, MD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Ezra EW. Cohen, MD | Clinical Trials In Progress | Antigen presenting cells;Checkpoint blockade;Clinical study;Clinical trial;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor evasion;Tumor microenvironment | |
| 440 | Poster Presentation | A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients unselected for PD-L1 expression in first line metastatic head and neck squamous cell carcinoma (HNSCC) | Julio A. Peguero, MD; Frederic Triebel, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell | |
| 441 | Poster Presentation | Population pharmacokinetics of an anti-PD-1 antibody, Penpulimab in patients with advanced malignancies | Benchao Chen, master; Xiaoping Jin; Yongcheng Dong, Ph.D; Max Wang; Dennis Xia, Ph.D; Michelle Xia, Ph.D; Baiyong Li, Ph.D | Clinical Trials In Progress | Antibody;Clinical study;Clinical trial;Leukemia/Lymphoma;Metabolism;Solid tumors | |
| 443 | Poster Presentation | Open-label, phase 2 study to assess the safety of mogamulizumab at 2 mg/kg Q4W maintenance dosing in patients with relapsed/refractory MF/SS subtypes of CTCL | Karen Dwyer, BA; Roland Meier, PhD; Matthew Hruska, PharmD, PhD; Floyd E. Fox, PhD; Takahiro Ito, MSc | Clinical Trials In Progress | Antibody;Clinical trial;COVID and Immunotherapy;Leukemia/Lymphoma;T cell;Targeted therapy | |
| 444 | Poster Presentation | GTB-3550 Tri-specific Killer Engager TriKE™ drives NK cells Expansion and Cytotoxicity in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients | Martin Felices, PhD; Erica Warlick, MD; Mark S. Juckett, MD; Daniel Weisdorf, MD; Daniel A. Vallera; Sarah Miller; Rose Wangen; Dixie Lewis, RN; JoAnne Knox; Martin Schroeder; Jeffrey S. Miller, MD; Jeffrey S. Miller MD | Clinical Trials In Progress | Bispecifics;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy | |
| 445 | Poster Presentation | Trial in progress: A phase 1b/2 study of alrizomadlin (APG-115), alone or combined with 5-azacitidine, in patients with relapsed/refractory acute myeloid leukemia (R/R AML) | Yifan Zhai; Tapan M. Kadia | Clinical Trials In Progress | Clinical trial;Leukemia/Lymphoma | |
| 447 | Poster Presentation | Interim results of a phase 1 study of the novel engineered toxin body TAK-169 in patients with relapsed or refractory multiple myeloma | Shaji Kumar, MD; Admasu Mamuye, MD, MSc; Kristina Dabovic, PharmD; Jingyuan Wang, PhD; Banmeet Anand, PhD; Amy Yuet, PhD; Bhagirathbhai Dholaria, MBBS; Vivek Roy, MD | Clinical Trials In Progress | Clinical study;Clinical trial;Leukemia/Lymphoma;Targeted therapy | |
| 448 | Poster Presentation | Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study | Edward A. Stadtmauer, MD, FACP; Lionel Karlin; Katja Weisel; Moshe Etzion Gatt; Ankit Kansagra; Gregory P. Monohan, MD; Andrew Yee; Shayna Rockow-Magnone; Jose Cordero; David Hoffman; Orlando Bueno; Kevin Y. Wu; Cristina Gasparetto, MD | Clinical Trials In Progress | Antibody;Chemotherapy;Clinical trial;Monocyte/Macrophage;Myeloid cells;Targeted therapy | |
| 449 | Oral Presentation | Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy | Jerill Thorpe, M.S.; Julie A. Rytlewski; Heidi H. Gillenwater; Ken Ogasawara; Yeonhee Kim; Diana Shpektor; Eniko Papp; Leanne Peiser | Clinical Trials In Progress | CAR T cells;Gene expression;Leukemia/Lymphoma;T cell;Targeted therapy | |
| 450 | Poster Presentation | Trial in progress: A phase 1b study of alrizomadlin, alone or plus 5-azacitidine or cytarabine, in pts with relapsed/refractory acute myeloid leukemia and relapsed higher-risk myelodysplastic syndrome | Yifan Zhai; Jianxiang Wang | Clinical Trials In Progress | Clinical trial;Leukemia/Lymphoma;Myeloid cells | |
| 452 | Poster Presentation | Preliminary analysis of a real-world study (RWS) of camrelizumab treatment in primary liver cancer (PLC) | Zhendong Chen; Nianfei Wang; Dayong Luo; Bo Jiang; Mu Yuan; Xinzhong Li; Chunmei Yao; Hong Qian; Qingsheng Kan; Erxuan Wang | Clinical Trials In Progress | Angiogenesis;Checkpoint blockade;Chemotherapy;Clinical trial;Coinhibition;Immune suppression;Targeted therapy | |
| 453 | Poster Presentation | Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma | Mark Yarchoan, MD; Edward Gane; Thomas U. Marron, MD, PhD; Sarah Rochestie; Neil Cooch; Joann Peters; Ildiko Csiki; ALFREDO PERALES-PUCHALT, MD, PhD; Niranjan Y. Sardesai | Clinical Trials In Progress | Clinical study;Clinical trial;Costimulation;Immune monitoring;Neoantigens;Solid tumors;Tumor antigens;Vaccine | |
| 454 | Poster Presentation | Analysis of NY-ESO-1 expression in specimens from a Phase I/II NY-ESO-1 T-cell therapy clinical trial in non-small cell lung cancer and from exploratory studies in multiple tumor types | Bryan Barnes; Ming Shan; Kristin Blouch; Mehmet Altan; Jaegil Kim; Natalia Ramos-Hernandez; Ellie Corigliano | Clinical Trials In Progress | Antibody;Biomarkers;CAR T cells;Clinical study;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 455 | Poster Presentation | Pegasus Lung, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with non-small cell lung cancer (NSCLC) and mesothelioma | Robin Meng, MD, PhD; Benjamin Besse, MD, PhD; Melissa L. Johnson, MD; Jaafar Bennouna, MD, PhD; Luca Toschi; Giovanni Abbadessa; Amele Amrate; Miao Zang; Luis Paz Ares, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;NK/NKT cell;Solid tumors;T cell | |
| 456 | Poster Presentation | A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with Stage IIIB/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress | Michael Boyer, MB BS PhD; Sandip Patel; Thomas U. Marron, MD, PhD; Nick Pavlakis; Sagun Parakh; Shirish Gadgeel; Michael Shafique, MD; Robert Hoyer; D Ross Camidge; Charles M. Farber, MD, PhD; Ranee Mehra, MD; Tarek Mekhail; Prunella Blinman; Karey Kowalski; Craig B. Davis, PhD; Dmitri Pavlov; Nayra Gad; Erminia Massarelli, MD, PhD, MS | Clinical Trials In Progress | Antibody;Clinical study;Clinical trial;Solid tumors | |
| 457 | Oral Presentation | KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC) | Martin Gutierrez, MD; Wei-Sen Lam; Matthew D. Hellmann, MD; Matthew Gubens, MD, MS; Charu Aggarwal, MD MPH; Daniel Shao Weng Tan; Enriqueta Felip, MD, PhD; Joanne W. Y. Chiu; Jong-Seok Lee; James Chih-Hsin Yang; Edward B. Garon; Giovanna Finocchiaro; Myung-Ju Ahn; Alexander Luft; Gregory A. Landers; Andrea Basso; Hua Ma; Julie Kobie; John Palcza, MS; Razvan Cristescu; Lawrence Fong, MD; Alexandra Snyder; Jianda Yuan, MD, PhD; Roy S. Herbst, MD, PhD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Gene expression;Solid tumors;Targeted therapy | |
| 458 | Poster Presentation | First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC) | Adam J. Schoenfeld, MD; Sylvia Lee, MD; Luis Paz-Ares; Bernard Doger; Scott N. Gettinger, MD; Simon Haefliger; Angela Orcurto, MD; Ammar Sukari, MD; Sophie Papa, PhD, MBBS, MRCP; Juan Francisco Rodriguez Moreno; Friedrich Graf Finckenstein, MD; Madan Jagasia; Rana Fiaz; Giri Sulur; Guang Chen; Viktoria Gontcharova, PhD; Kai He, MD, PhD | Clinical Trials In Progress | Adoptive immunotherapy;Clinical study;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 459 | Poster Presentation | Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC | Matthew D. Hellmann, MD; Byoung C. Cho, MD, PhD; Rosalyn A. Juergens, MD, PhD; Ying Cheng, MD; Gilberto de Castro, Jr; Mustafa Erman, MD; Jessica Bauman; Toshiaki Takahashi, MD, PhD; Paul Schwarzenberger, MD; Pingye Zhang, PhD; M. Catherine Pietanza; James Chih-Hsin Yang | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemotherapy;Clinical trial | |
| 460 | Poster Presentation | Spatial distribution of infiltrating T lymphocytes with Immunoscore® CR T Cells Exhaustion test helps stratification of NSCLC patients treated with PD1 / PDL1 inhibitors in the PIONeeR project | Vanina Leca, PhD; Alboukadel Kassambara, PhD; Lamia Ghezali, PhD; Pernelle Outters; Christelle Cotteaux-Lautard; Fanny Arnoux, PhD; Thomas Sbarrato, PhD; Florence Monville, PhD; Maryannick Le Ray, PharmD; Marie Roumieux, PhD; Stephane Garcia; Richard Malkoun; Noémie Resseguier; Arnaud Boyer; Louisiane Lebas; Hervé Pegliasco; Patricia Barré; Clarisse Audigier-valette; Sarah Zahi; Luc Odier; Stéphane Hominal; Maurice Perol; Julien Mazieres; Laurent Greillier; Fabrice Barlesi, Prof, MD, PhD; Jacques Fieschi-Meric, PhD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical study;Immune contexture;Immunoscore;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 461 | Poster Presentation | Updated PFS analysis of toripalimab with anlotinib and chemotherapy as first-line therapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) | Hao Luo, MD; Dan Jian; Yan Feng; Li Zhong; Qian Chen; Wei Guan; Shiheng Zhang; Jiamin Luo; Xueqin Yang; Kan Gong; Yanli Xiong; Mengxia Li; Mingfang Xu; Yu Pu; Liang Zhao; Chengyuan Qian; Nan Dai; Dong Wang | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Solid tumors | |
| 462 | Poster Presentation | A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data | Magnus Jaderberg; Luis Paz-Ares; Susana Cedres, MD; Charles Ricordel, MD; Nicolas Isambert; Santiago Ponce Aix; Victor Levitsky, MD, PhD; Lukasz Kuryk, PhD; Anne-Sophie Moller; Sylvia Vetrhus | Clinical Trials In Progress | Clinical trial;Gene expression;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 463 | Poster Presentation | Vibostolimab plus pembrolizumab with/without docetaxel vs docetaxel in NSCLC after platinum chemotherapy and immunotherapy | Solange Peters, MD, PhD; Dae Ho Lee, MD, PhD; Rodryg Ramlau, MD, PhD; Balazs Halmos, MD; Christian Schumann, MD, PhD; David Planchard, MD, PhD; Niyati Bhagwati, MD; Diana (Qiusheng) Chen, PhD; Debra Kush, BSN, MBA; Silvia Novello, MD, PhD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemotherapy;Clinical trial | |
| 464 | Poster Presentation | 2SMALL (NCT04253145) phase I part: Lurbinectidine (LUR) in combination with Atezolizumab (ATZ) for second line Extensive Stage Small Cell Lung Cancer (ES-SCLC) patients (pts) | Santiago Ponce Aix, MD; Alejandro Navarro; Reyes Bernabe; Maria Eugenia Olmedo; Trigo Jose Manuel; Jon Zugazagoitia Fraile, MD; Luis Paz-Ares; Santiago Ponce Aix | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical trial;Solid tumors | |
| 465 | Poster Presentation | Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety and pharmacokinetic results of the INTR@PID LUNG 024 study | Christian Rolfo, MD, PhD, MBA, Dr.hc.; Laurent Greillier; Remi Veillon; Firas Badin, MD; Francois Ghiringhelli; Nicolas Isambert, MD, PhD; Astrid Paulus; Marc Lambrechts; Surendra Chaudhary; Xiaoli You; Yulia Vugmeyster; Christoph Helwig, MSc; Sandrine Hiret | Clinical Trials In Progress | Bispecifics;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Coinhibition;Solid tumors | |
| 466 | Poster Presentation | Use of a 27-gene immuno-oncology (IO) assay to associate response to single-agent immune checkpoint inhibitor (ICI) therapy in advanced-stage NSCLC patients from a large Canadian cohort. | David L. Saltman, MD PhD; Nicole S. Croteau, MSc; Heather M. Lockyer; Rob S. Seitz; Frank B. McMahon; Jeremy Spille; Andrea Dickey; Matthew G. Varga, PhD; Kim McGregor, MD; Tyler J. Nielsen, MS; David R. Hout, PhD; Brock L. Schweitzer, PhD; Douglas T. Ross, MD, PhD; David Gandara, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Gene expression;RNA;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 467 | Poster Presentation | Phase II clinical study of Toripalimab in combination with stereotactic radiotherapy as a neoadjuvant therapy for the treatment of resectable (N1-N2) non-small cell lung cancer | Zhen Wang, MD; Xi-xu Zhu; Yong Song | Clinical Trials In Progress | Clinical study;Immune suppression;Radiotherapy;Solid tumors | |
| 468 | Poster Presentation | A phase Ⅱ study of toripalimab plus anlotinib as maintenance therapy in extensive-stage small cell lung cancer | Dongqing Lv, MD; Guixian Wu | Clinical Trials In Progress | Angiogenesis;Checkpoint blockade;Chemotherapy;Clinical study | |
| 469 | Poster Presentation | A Phase 1 First in Human Study of HMBD-002, an IgG4 Monoclonal Antibody Targeting VISTA, as a Monotherapy and Combined with Pembrolizumab in Patients with Advanced Solid Malignancies | Leah DiMascio, PhD; Dipti Thakkar, PhD; Siyu Guan, PhD; Eric Rowinsky, MD; Jordi Rodon; Joshua J. Gruber, MD, PhD; Benjamin L. Musher, MD; Joseph W. Kim, MD; Alain Mita, MD; Monica Mita, MD; Piers J. Ingram, PhD; Jerome D. Boyd-Kirkup, PhD | Clinical Trials In Progress | Antibody;Checkpoint blockade;MDSC;Myeloid cells;Solid tumors;Tumor microenvironment | |
| 470 | Poster Presentation | A Phase 1/2, Open-Label, Dose Escalation and Expansion Study of GI-101 as a Single Agent and in Combination with a Pembrolizumab, Lenvatinib or Local RT in Advanced Solid Tumors (KEYNOTE-B59) | Byoung Chul Cho, MD, PhD; Sang Joon Shin, MD, PhD; Jae-Lyun Lee, MD, PhD; Byoung Yong Shim, MD, PhD; Hyung Soon Park, MD, PhD; Nari Yun, PhD; Mina Ham, MS; Young Jun Koh, PhD; Myoung Ho Jang, PhD | Clinical Trials In Progress | Bispecifics;Checkpoint blockade;Clinical trial;Cytokine;Radiotherapy;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 471 | Poster Presentation | Pharmacokinetics of first and repeated dosing of non-irAE-inducing anti-CTLA-4 monoclonal antibody ONC-392 in advanced cancer patients | Hung-Yen Chou, PhD; Tianhong Li, MD, PhD; Karen Kelly, MD; Anthony Martinez; Stacy S. Joo; Mei Tang, MD, PhD; Martin Devenport; Yang Liu, PhD; Pan Zheng, MD, PhD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical study;Immune toxicity;Regulatory T cell (Treg cell);Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 472 | Poster Presentation | BDB001, a Toll-Like Receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously in combination with atezolizumab and shows clinical responses in advanced solid tumors | Manish R. Patel, MD; Drew Rasco, MD; Melissa L. Johnson, MD; Anthony Tolcher, MD; David Sommerhalder, MD; Omid Hamid, MD; Alexander Chung, PhD; Lixin Li, PhD; Robert H. Andtbacka, MD, CM | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell;TLR | |
| 473 | Poster Presentation | Immune profiling of patients with advanced solid tumors treated with intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in Phase I clinical trial | Paula L. Codó, Dr. sc. nat.; Thomas Eigentler, Prof. Dr.; Lucie Heinzerling, Prof. Dr. Med.; Juergen Krauss, Prof. Dr. med.; Carsten Weishaupt, P.D. Dr. med; Sebastian Ochsenreither, P.D. Dr.; Celeste Lebbe, MD, PhD; Peter Mohr, Dr.; Marc Oliva; Honey K. Oberoi, M.D.; Patrick Terheyden, P.D. Dr. med.; José M. Trigo Pérez; Franz-Georg Bauernfeind, Dr. med.; Michael Fluck, Dr. med.; Erika Richtig, Prof. Dr.; Ainara Soria, MD; Marina Gonzalez; Fatma Funkner, Dr.; Peter Wengenmayer; Dominik Vahrenhorst; Tobias Seibel, II, Dr.; Gianluca Quintini, Dr.; Beate Schmitt-Bormann, Dr. med.; Birgit Scheel, Dr.; Martin H. Falk, Dr.; Ulrike Gnad-Vogt, Dr. med. | Clinical Trials In Progress | Clinical study;Clinical trial;Cytokine;Gene expression;Immune monitoring;RNA;Solid tumors;TLR;Tumor microenvironment | |
| 474 | Poster Presentation | Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress) | Diwakar Davar; Vincent Ribrag, MD; Clementine Sarkozy, MD, PhD; Elena Garralda; Honey Kumar Oberoi, MD, MSc; Amitkumar Mehta, MD; Giuseppe Curigliano, MD, PhD; Carmen Belli, MD, PhD; Jasmine Zain, MD; Alex F. Herrera, MD; Rachel E. Sanborn, MD; Ecaterina E. Dumbrava, MD; Andres Forero-Torres, MD; Stephen M. Ansell, MD, PhD | Clinical Trials In Progress | Antibody;Clinical trial;Leukemia/Lymphoma;Regulatory T cell (Treg cell);Solid tumors;T cell;Targeted therapy | |
| 475 | Poster Presentation | GEN-011-101 (the TiTAN-1 trial): Phase 1 study to evaluate the safety, proliferation and persistence of GEN-011, an autologous neoantigen-targeted peripheral T cell therapy in solid tumors | Thomas A. Davis, MD; Arthur P. DeCillis, MD; Richard Hernandez; Jessica Price; Craig Carey; Kevin J. Mancini, MS | Clinical Trials In Progress | Adoptive immunotherapy;CAR T cells;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 476 | Poster Presentation | First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results | Arkadiusz Z. Dudek, MD, PhD; Dejan Juric; Afshin Dowlati; Ulka Vaishampayan, MD; Hadeel Assad; Jordi Rodón; Bo Chao; Bingxia Wang; John Gibbs; Vaishali M. Shinde; Sharon Friedlander; Allison J. Berger, PhD; Christine K. Ward; Alonzo Martinez; Robert Gharavi; Alejandro Gomez-Pinillos; Igor Proscurshim; Anthony J. Olszanski, MD, RPh | Clinical Trials In Progress | Clinical trial;Immune adjuvant;Leukemia/Lymphoma;Post-translational modifications;Solid tumors | |
| 477 | Poster Presentation | COM902 (Anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics and receptor occupancy in patients with advanced solid tumors (NCT04354246). | Ecaterina E. Dumbrava, MD; Drew Rasco, MD; Amita Patnaik, MD; Daniel Vaena; Kyriakos P. Papadopoulos, MD; Adam ElNaggar; Adeboye H. Adewoye, MD; Robina Smith; Pierre Ferré, Dr Vet Med, PhD; Ilan Vaknin, PhD; Srinivas Devarakonda, MD; Manish R. Sharma, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;NK/NKT cell;T cell | |
| 478 | Poster Presentation | COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab - preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839) | Ecaterina E. Dumbrava, MD; Manish R. Sharma, MD; Gini Fleming, MD; Kyriakos P. Papadopoulos, MD; Ryan J. Sullivan, MD; Daniel Vaena; Amita Patnaik, MD; Adam ElNaggar; Adeboye H. Adewoye, MD; Robina Smith; Pierre Ferré, Dr Vet Med; Inbal Barbiro; Emerson Lim, MD.; Drew Rasco, MD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical study;Clinical trial;T cell | |
| 479 | Poster Presentation | AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results | Anthony El-Khoueiry, MD; Andrea J. Bullock, MD; Apostolia M. Tsimberidou, MD, PhD; Daruka Mahadevan; Breelyn A. Wilky, MD; Przemyslaw W. Twardowski; Bruno Bockorny; Justin Moser, MD; Waldo Ortuzar Feliu, MD; Joseph E. Grossman; Katherine Rosenthal; Steven J. O'Day; Michael S. Gordon | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical trial;Solid tumors;Targeted therapy | |
| 480 | Poster Presentation | A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6 | Gerald S. Falchook, MD, MS; David R. Spigel, MD; Manish R. Patel, MD; Babar Bashir, MD, MS; Susanna Ulahannan, MD, MMED; Christine Duffy; Daniela Maier; Hisaya Azuma | Clinical Trials In Progress | Clinical trial;Coinhibition;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 481 | Poster Presentation | Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanced solid tumors | Gerald S. Falchook, MD, MS; Hui K. Gan, MBBS PhD; Siqing Fu, MD, PhD; Meredith McKean, MD; Arun Azad, MD; David Sommerhalder; Judy S. Wang, MD; Tira Tan; Chen E. Chee; Minal Barve, MD; charlotte Lemeque; Nicole Acuff; Helene Pham; Jill Mooney; Rui Wang; Neyssa Marina, MD, MS; Giovanni Abbadessa, MD; Tarek Meniawy, MBBS FRACP | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;NK/NKT cell;Solid tumors | |
| 482 | Poster Presentation | Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in Patients With Metastatic Solid Tumors | Aleksandra Filipovic, MD, PhD; Zev A. Wainber, MD; Judy S. Wang, MD; Johanna C. Bendell, MD; Filip Janku, MD, PhD; Manish R. Sharma, MD; Amit Mahipal; Joseph Bolen, PhD; Eric Elenko; Christopher Korth; George Dranitsaris | Clinical Trials In Progress | Antibody;Biomarkers;Clinical trial;Immune monitoring;Immune suppression;Solid tumors;Tumor microenvironment | |
| 483 | Poster Presentation | Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers | Charalampos Floudas, MD, DMSc, MS; Julius Strauss, MD; Clint T. Allen, MD; Renee N. Donahue, PhD; Caroline Jochems, MD, PhD; Seth Steinberg, PhD; Lisa Cordes, PharmD, BCACP, BCOP; Douglas E. Brough, PhD; Amy Lankford, PhD; Sheri McMahon, RN; Jenn Marte, MD, MPH; Jason M. Redman, MD; Fatima Karzai, MD; Ravi A. Madan, MD; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Solid tumors;T cell;Vaccine | |
| 484 | Poster Presentation | Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors | Elena Garralda, MD, MSc; Vladimir Galvao, MD; Stephane Champiat; Patricia LoRusso; Peter Grell; Aung Naing, MD; Filip Janku; Richard Sachse; David Bechard; Joachim Kiemle-Kallee; Aurelien Marabelle; Elena Garralda | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Costimulation;Cytokine;Solid tumors | |
| 485 | Poster Presentation | Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors | Maura L. Gillison, MD, PhD; Mark Awad, MD, PhD; Przemyslaw Twardowski, MD; Ammar Sukari, MD; Melissa L. Johnson, MD; Rudy Lackner, MD; Mark N. Stein, MD; Arthur P. DeCillis, MD; Richard Hernandez; Jessica Price; Kevin J. Mancini, MS; Mara G. Shainheit, Ph.D.; Gabriella Santone, MS; Syukri Shukor; Ece Bicak, MS; Vijetha Vemulapalli; Emily Tjon, M.S.; Jessica B. Flechtner, PhD; Thomas A. Davis, MD; Roger B. Cohen, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;Tumor antigens;Vaccine | |
| 487 | Poster Presentation | NC410, a fusion protein of LAIR-2 (Leukocyte Associated Immunoglobulin-like Receptor) with human IgG1 Fc, is safe & tolerable with evidence of immune modulation in subjects with advanced solid tumors | Han Myint, MD, FRCPath, FRCP; Linjie Tian, PhD; Jahangheer S. Shaik, Ph.D.; Emilia A. Barbu, Ph.D.; Qinjie Zhou, Ph.D.; Aaron Morawski; Hasan Abukharma; Linda N. Liu, PhD; John Shin, MD; Dallas B. Flies, PhD; Ron Copeland, Ph.D.; Megan Nelson; Stephanie Zeidan; Marijo Bilusic, MD; Danielle Pastor, DO, Ph.D.,; Ravi A. Madan, MD; Siqing Fu, MD, PhD; Martin Gutierrez, MD; Solomon Langermann, PhD | Clinical Trials In Progress | Antibody;Biomarkers;Checkpoint blockade;Clinical trial;Immune suppression;Myeloid cells;Solid tumors;T cell;Tumor microenvironment;Tumor stroma | |
| 488 | Poster Presentation | Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors | Omid Hamid, MD; Dawn Baxter; Rachael Easton; Lilian L. Siu, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Targeted therapy | |
| 489 | Poster Presentation | TWT-101: A Phase 1 Study of the Novel HPK1 Inhibitor CFI-402411 in Patients with Advanced Cancer | Omid Hamid, MD; Johanna Bendell; Siqing Fu, MD, PhD; Kyriakos P. Papadopoulos, MD; Judy S. Wang, MD; Brigette Ma, MD; Anna Spreafico, MD PhD; Alexander I. Spira, MD, PhD, FACP; Mark R. Bray; Graham Fletcher; Glenn Michelson; Emily Roberts-Thomson, MMSc | Clinical Trials In Progress | Clinical study;Clinical trial;Cytokine;Regulatory T cell (Treg cell);Solid tumors;T cell;Targeted therapy | |
| 490 | Oral Presentation | Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors | Elaine Shum, MD; Han Myint, MD, FRCPath, FRCP; Jahangheer S. Shaik, Ph.D.; Qinjie Zhou, Ph.D.; Emilia A. Barbu, Ph.D.; Aaron Morawski; Hasan Abukharma; Linda N. Liu, PhD; Megan Nelson; Stephanie Zeidan; Zachary Cusumano, Ph.D.; Anthony Tolcher, MD; Solomon Langermann, PhD; Martin Gutierrez, MD; Omid Hamid, MD | Clinical Trials In Progress | Antibody;Biomarkers;Checkpoint blockade;Clinical trial;Immune suppression;Myeloid cells;Solid tumors;T cell;Tumor microenvironment | |
| 491 | Poster Presentation | BASECAMP-1: An observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy | Julian R. Molina, MD, PhD; William Y. Go, MD, PhD; Scott Kopetz, PhD; Diane M. Simeone, MD; Sandip Patel; Yi Lin, MD PhD; Kirstin B. Liechty; Michelle Fan-Port, PhD; Jason Perera, PhD; Armen Mardiros, PhD; Karl Beutner; Ariane Lozac’hmeur; Eric Ng, MD; David G. Maloney, MD, PhD; J. Randolph Hecht, MD | Clinical Trials In Progress | Adoptive immunotherapy;CAR T cells;Clinical study;Clinical trial;Epidemiology;Solid tumors;T cell;Tumor antigens | |
| 492 | Oral Presentation | Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers | David O'Malley; Sylvia Lee, MD; Amanda Psyrri; Ammar Sukari, MD; Sajeve S. Thomas; Robert Wenham, MD, MS, FACS, FACOG; Helen Gogas, MD, PhD; Amir Jazaeri, MD; Bradley J. Monk, MD FACOG FACS; Peter Rose; Antonio Reuda; Friedrich Graf Finckenstein, MD; Madan Jagasia; Rana Fiaz; Brigid Garelik, MD, MPH; Wen Shi, MD, PhD; Anjali Desai; Giri Sulur; Guang Chen; Xiao Wu; Antonio Jimeno, MD, PhD | Clinical Trials In Progress | Adoptive immunotherapy;Checkpoint blockade;Clinical study;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 493 | Oral Presentation | First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4-1BB (GEN1042) in patients with advanced solid tumors | Melissa Johnson; Juanita Lopez; Patricia LoRusso; Jessica Bauman; Daniel Haggstrom; Eleni Lagkadinou; Gaurav Bajaj; Özlem Türeci; Homer C. Adams III; Ugur Sahin; Yali Fu; Tahamtan Ahmadi; Kristoffer S. Rohrberg | Clinical Trials In Progress | Antibody;Bispecifics;Clinical trial;Costimulation;Dendritic cell;Solid tumors;T cell | |
| 494 | Poster Presentation | Phase 1 dose escalation and dose expansion study of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas | Melissa L. Johnson, MD; Lilian L. Siu, MD; David S. Hong, Professor; Patrick Schoffski; Vladimir Galvao, MD; Fatima Rangwala, MD, PhD; Robert Hernandez, PhD; Louis E. Gonzalez, PhD; Bo Ma, PhD; Lini Pandite, MD; Irene Brana, MD | Clinical Trials In Progress | Biomarkers;Bispecifics;Checkpoint blockade;Clinical trial;Costimulation;Solid tumors | |
| 495 | Poster Presentation | Trial of SNX281, a systemically delivered small molecule STING agonist, in solid tumors and lymphomas. | Judy S. Wang, MD; Gerald S. Falchook, MD, MS; Salah Nabhan, MS; Meghana M. Kulkarni, PhD; Peter M. Sandy; Ololade Dosunmu, MD; Humphrey A. Gardner, MD, FCAP; Johanna C. Bendell, MD; Melissa L. Johnson, MD | Clinical Trials In Progress | Checkpoint blockade;Dendritic cell;Immune adjuvant | |
| 496 | Poster Presentation | Toxicity of an Fc engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable anti-tumor immunity in patients | David Knorr, MD, PhD; Jeffrey V. Ravetch, MD, PhD; Gabriela D'Andrea, MD; Linda T. Vahdat, MD; Christopher A. Klebanoff, MD; Mark Robson | Clinical Trials In Progress | Antibody;Antigen presenting cells;Clinical trial;Dendritic cell | |
| 497 | Poster Presentation | A Study of ALPN-202, a PD-L1-dependent CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in patients with advanced malignancies | Nehal J. Lakhani, MD; Meredith McKean, MD; Amita Patnaik, MD FRCP(C); Kristi Manjarrez; Hany Zayed, PhD; Michael Chisamore, PhD; Stanford Peng, MD, PhD; Zelanna Goldberg, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Costimulation;Solid tumors;T cell | |
| 498 | Poster Presentation | Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01 | Keun-Wook Lee, MD; Hyun C. Chung, MD, PhD; Tae Min Kim, MD, PhD; Nehal J. Lakhani, MD; Wells A. Messersmith, MD; Rafael Santana-Davila, MD; Won Seog Kim, MD; Patricia LoRusso; Yung-Jue Bang, MD PhD; Laura QM. Chow, MD; Philip S. Fanning, PhD; Pierre Squifflet, MS; Feng Jin, PhD; Alison J. Forgie, PhD; Hong I. Wan, PhD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Justin Gainor, MD | Clinical Trials In Progress | Antigen presenting cells;Checkpoint blockade;Chemotherapy;Clinical trial;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Targeted therapy | |
| 499 | Poster Presentation | A first-in-human, phase 1/2 clinical trial of TK-8001, a MAGE-A1 directed T cell receptor in patients with advanced-stage solid tumors (The „IMAG1NE“-trial) | Fiona Thistlethwaite, MD, PhD; Antonia Busse, MD, PhD; Emiliano Calvo, MD, PhD; Marie-Luise Goebeler, MD; Martin Wermke; Sylvie Rottey, MD; Nuria Kotecki, MD; Matthias Obenaus, MD; Vivian Scheuplein, PhD; Ralf Wolter, PhD; Carolina Perdomo-Ortiz, PhD; Ioannis IG. Gavvovidis, PhD; Elisa Kieback, PhD; Thomas Blankenstein, PhD; Eugen Leo, MD PhD MBA | Clinical Trials In Progress | Adoptive immunotherapy;Antigen presenting cells;Biomarkers;Clinical study;Clinical trial;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 500 | Poster Presentation | SYNB1891, a bacterium engineered to produce a STING agonist, demonstrates target engagement in humans following intratumoral injection | Richard Riese, MD, PhD; Jason J. Luke; Karl Lewis, MD; Filip Janku, MD, PhD; Sarina A. Piha-Paul, MD; Claire F. Verschraegen, MD; Aoife M. Brennan, MD; Michael MB. Armstrong, MD; Mary Varterasian, MD; Anna Sokolovska, PhD; James F. Strauss, MD | Clinical Trials In Progress | Clinical trial;Immune adjuvant;Microbiome | |
| 501 | Poster Presentation | Survival and Immune Response Data from Intratumoral INT230-6 Alone (IT-01) and with Pembrolizumab [KEYNOTE-A10] in Subjects with Locally Advanced, Unresectable and Metastatic Solid Tumors | Jacob Thomas, MD; Anthony El-Khoueiry, MD; Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Giles F. Whalen, MD; Diana Hanna, MD; Matthew Ingham, MD; Syed Mahmood, MD; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Lilian L. Siu, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Solid tumors | |
| 502 | Poster Presentation | Recommended phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the IL-15 superagonist SO-C101 as monotherapy in patients with advanced/metastatic solid tumors | Aurelien Marabelle; Stéphane Champiat; Vladimir Galvao, MD; Aung Naing, MD; Filip Janku; Patricia LoRusso; Peter Grell; Richard Sachse; David Bechard; Joachim Kiemle-Kallee; Ellena Garralda | Clinical Trials In Progress | Clinical trial;Costimulation;Cytokine;Solid tumors | |
| 503 | Oral Presentation | Clinical Activity of ICT01, an anti-BTN3A-Targeted, γ9δ2-Activating mAb, Alone and in Combination with Pembrolizumab in Patients with Advanced/Refractory Solid Tumors: EVICTION Trial | Martin Wermke; Aurelien Marabelle; Christiane Jungels, MD; Johann S. De Bono, PhD; Norbert Vey, MD; Cécile Vicier; Elena Garralda; Steven Le Gouill; Patricia LoRusso; Stephane Champiat; Catrin List; Vladimir Galvaö de Aguiar; Katrin Wetzko; Leo Rhunke; Aude de Gassart, PhD; Patrick Brune; Emmanuel Valentin, PhD; Marina Iche; Daniel OLIVE, M.D., Ph.D.,; Paul A. Frohna, MD, PhD, PharmD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical study;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 504 | Poster Presentation | A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER) | Ignacio J. Melero, Dr., MD, PhD; Emiliano Calvo; Maria-Elisabeth Goebeler, MD; Elena Garralda; Reinhard Dummer, MD; María Rodríguez-Ruiz, MD; Maria J. de Miguel, MD, PhD; Cyrus Michael Sayehli, MD; Guzman Alonso Casal, MD; Egle Ramelyte, MD; Martin Schuler, MD; Tanja Gromke, MD; Miguel Sanmamed, MD, PhD; Irene Moreno, MD, PhD; Ralf Bargou, MD, PhD; Maria Lostes, MD; Julia-Tatjana Maul, MD; Corinne Eggenschwiler, MD; Heike Richly, MD; Petra Fettes, PhD; Kathrin Klar, PhD; Christine Schuberth-Wagner, PhD; Markus Haake, PhD; Jörg Wischhusen, PhD; Eugen Leo, MD PhD MBA | Clinical Trials In Progress | Antibody;Antigen presenting cells;Checkpoint blockade;Clinical trial;Immunoscore;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 505 | Poster Presentation | Relationship of infusion duration and dose to safety, efficacy and pharmacodynamics: second part of a phase 1-2 study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors | Manish R. Patel, MD; Steven F. Powell; James F. Strauss, MD; Melissa Johnson; Timothy P. Cripe; Kah-Whye Peng; Stephen J. Russell; Luke Russell; Monica Reckner; Erol Wiegert; Alice S. Bexon; Jaime R. Merchan, MD | Clinical Trials In Progress | Clinical trial;Targeted therapy;Vaccine | |
| 506 | Poster Presentation | IGNYTE: An open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors | Mark R. Middleton, MD, PhD; Mohammed M. Milhem, MBBS; Francesca Aroldi, MSc; Joseph J. Sacco, MD PhD; Ari M. VanderWalde, MD, MPH, MBioeth; Scott Baum; Adel Samson, PhD; Jason A. Chesney, MD; Jiaxin Niu; Terence Rhodes, MD, PhD; Tawnya L. Bowles, MD; Hamid Emamekhoo, MD; Katy K. Tsai, MD; Gino K. In, MD, MPH; Georgia M. Beasley, MD, MHs; Bartosz Chmielowski; Sophie Dalac-Rat, MD; Katharina Kahler; Eva Muñoz, MD, PhD; Anna C. Olsson-Brown, MD; Praveen K. Bommareddy, MS, PhD; Lavita Menezes, MSc; Andrea Pirzkall, MD; Robert S. Coffin, PhD; Kevin Harrington, PhD, FRCP, FRCR | Clinical Trials In Progress | B cell;Clinical trial;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 507 | Poster Presentation | A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors | Mark R. Middleton, MD, PhD; Joseph J. Sacco, MD PhD; Kevin Harrington, PhD, FRCP, FRCR; Anna C. Olsson-Brown, MD; Tze Y. Chan, MBChB; Pablo Nenclares; Isla Leslie; Francesca Aroldi, MSc; Praveen K. Bommareddy, MS, PhD; Imran Saleem; Henry Castro; Andrea Pirzkall, MD; Robert S. Coffin, PhD | Clinical Trials In Progress | B cell;Checkpoint blockade;Clinical study;Neoantigens;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 509 | Poster Presentation | A first-in-human Phase 1 study of NL-201 in patients with relapsed or refractory cancer | Aung Naing, MD; Margaret K. Callahan, MD, PhD; Brian Costello, MD; Carlo D. Bifulco, MD; Evan T. Hall, MD, MPhil; Aaron Hansen, MD; Georgina V. Long, MBBS, PhD, BSc, FRAC; Anthony M. Joshua, MBBS, PhD; Brooke Shankles, MA; Umut Ulge, MD, PhD; Andrew Weickhardt, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 510 | Poster Presentation | SO-C101, a high-affinity IL-15Rbg agonist, induces safe and potent anti-tumor immune activities in patients with solid tumors and supports further clinical investigations. | Lenka Palová, PhD | Clinical Trials In Progress | Clinical study;Immune monitoring;NK/NKT cell;Solid tumors;T cell | |
| 511 | Poster Presentation | Initial results of a Phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors | Jong Chul Park, MD; Hatem Soliman, MD; Gerald S. Falchook, MD, MS; Taofeek K. Owonikoko, MD, PhD; Anna Spreafico, MD PhD; Erminia Massarelli, MD, PhD, MS; Meredith McKean, MD; Laura QM. Chow, MD; Patrick A. Ott, MD, PhD; Robert Wesolowski, MD; Christos Fountzilas, MD, FACP; Corey Whalen; Adrienne G. Yanez, PhD; Christopher D. Dupont, PhD; Julia Auer, MA; Tooba Cheema, PhD; John M. Goldberg, MD; Ted T. Ashburn, MD, PhD; Igor Puzanov, MD, MSCI | Clinical Trials In Progress | Checkpoint blockade;Chemokine;Clinical trial;Cytokine;Dendritic cell;Immune toxicity;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment | |
| 512 | Poster Presentation | Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in metastatic and advanced solid tumors | Jason J. Luke; Anthony J. Olszanski, MD, RPh; Igor Puzanov, MD, MSCI; Christos Fountzilas, MD, FACP; Lee Rosen; Dan Lu, MS; Adrian Hackett; Stella Martomo, PhD; Olivier Schueller; David Eiznhamer; Alessandro Mora; Miranda Ross; Jeegar Patel | Clinical Trials In Progress | Antibody;Biomarkers;Clinical study;Clinical trial;Regulatory T cell (Treg cell);Solid tumors | |
| 513 | Poster Presentation | Trial in progress: Phase 1 first-in-human study of XL092 administered alone or in combination with immune checkpoint inhibitors in patients with inoperable locally advanced or metastatic solid tumors | Amita Patnaik, MD; Vivek Subbiah, MD; Geoffrey I. Shapiro, MD, PhD; Sumanta K. Pal, MD; Neeraj Agarwal, MD; Kristopher Wentzel, M.D.; Jing Li; Elizabeth McIlvaine; Jana Waldes; Edward Cha, MD, PhD; Keyvan Tadjalli-Mehr; Manish R. Sharma, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Targeted therapy | |
| 515 | Poster Presentation | A phase 1 study of myeloid modulating agent MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours | Ruth Plummer; Mikael H. Sodergren, MD, PhD; David J. Pinato, MD, MRes, PhD; Debashis Sarker; Vikash Reebye; Duncan Spalding; Nina Raulf; Laura Sinigaglia; Thomas Talbot; Alessio AC. Cortellini, MD; Antonio D'Alessio; Ilian Tchakov; Robert Habib; John Rossi; Nagy Habib | Clinical Trials In Progress | Monocyte/Macrophage;RNA;Solid tumors | |
| 516 | Poster Presentation | Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4-1BB (GEN1046) trial | Santiago Ponce Aix; Emiliano Calvo; Victor Moreno; Elena Garralda; Andrés Cervantes; Suresh S. Ramalingam; José M. Trigo Pérez; Patricia LoRusso; Muhammad Furqan; Daniel Cho; Alexander Muik; Eleni Lagkadinou; Özlem Türeci; Suzana Couto; Nora Pencheva; Ulf Forssmann; Ugur Sahin; Tahamtan Ahmadi; Brandon Higgs; Maria Jure-Kunkel; Ignacio J. Melero, Dr., MD, PhD | Clinical Trials In Progress | Antibody;Bispecifics;Clinical trial;Costimulation;Solid tumors;T cell | |
| 517 | Poster Presentation | LUMINOS-103: A basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors | Brant A. Inman, MD, MS; Matthew I. Milowsky, MD; Raj S. Pruthi; Marshall R. Posner, MD; Melissa J. Polasek; Shannon Morris, MD, PhD; Lori Mixson; Kristin Orr; Elizabeth Woodson; Andrea T. Kelly; Garrett Nichols; Arjun V. Balar, MD | Clinical Trials In Progress | Antigen presenting cells;Checkpoint blockade;Clinical trial;Cytokine;Dendritic cell;Inflammation;Monocyte/Macrophage;Solid tumors;T cell;Tumor microenvironment | |
| 518 | Poster Presentation | First-in-human results with the novel tumor-targeting antibody ATRC-101: phase 1b study in patients with solid tumors | John D. Powderly, II, MD; Jeremy Jones; Tanios S. Bekaii-Saab, MD; Yan Xing, MD, PhD; S. John Weroha, MD, PhD; Susanna Ulahannan, MD, MMED; Deborah Doroshow; Frances Valdes-Albini; Carl Millward, MD; Kimberly Walter; Andrew Wrong; Paul Del Castillo; Lixia Wang; Ngan Nguyen; Mark Whidden, PhD; Jonathan Benjamin, MD, PhD; Steven J. Isakoff, MD, PhD | Clinical Trials In Progress | Antibody;Biomarkers;Clinical trial;Solid tumors;T cell;Targeted therapy | |
| 519 | Poster Presentation | A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 in Patients with Advanced Solid Tumors | John D. Powderly, II, MD; Teleen Norman; Meghan Duncan; Martin Huber, MD; Jennifer O'Neil, PhD; Ekta Patel, PhD; Andrae Vandross, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Solid tumors;Tumor microenvironment | |
| 520 | Poster Presentation | Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors | Debbie Robbrecht; Grob Jean-Jacques; Oliver Bechter; Armando Santoro; Bernard Doger; Ivan Borbath; Butler Marcus; Cheng Tina; Patricia Martin; Bennouna Jaafar; Massimo Di Nicola; Giuseppe Curigliano, MD, PhD; Min-Hee Ryu; Alejo Rodriguez -Vida; Dirk Schadendof; Elena Garralda; Giovanni Abbadessa; Brigitte Demers, MD; Amele Amrate; Tun Tun Lin; Manisha Brahmachary; Joon Sange Lee; Joachim Theilhaber; Debbie Robbrecht, MD; Rui Wang | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Immune monitoring;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 521 | Poster Presentation | GEN-009, a personalized neoantigen vaccine candidate, elicits diverse and durable immune responses associated with clinical efficacy outcomes | Mara G. Shainheit, Ph.D.; Ece Bicak, MS; Masoud Golshadi, Ph.D.; Gabriella Santone, MS; Syukri Shukor; Emily Tjon, M.S.; Li Xue, Ph.D.; Thomas A. Davis, MD; Jessica B. Flechtner, PhD | Clinical Trials In Progress | Biomarkers;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;T cell;Vaccine | |
| 522 | Poster Presentation | Transcriptomic changes in cancer patients treated with immune-checkpoint inhibitors. | Dmitrii Dr. Shek, MD, MRes; Bo Gao; Joey Lai, BSc, MSc, PHD; Won-Hee Yoon, MD; Tania Moujaber, MBBS, PhD, FRACP; Adnan Nagrial, MBBS, PhD, FRACP; Matteo S. Carlino, M.D., Ph.D.; Scott A. Read, BSc, MSc, PhD; Golo Ahlenstiel, MD, PhD, FRACP | Clinical Trials In Progress | Bioinformatics;Biomarkers;Immune toxicity;RNA;T cell | |
| 523 | Poster Presentation | Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors | Elaine Shum, MD; Matthew J. Reilley, MD; Yana G. Najjar, MD; Adil I. Daud, MD; John A. Thompson, MD; Joaquina Baranda; R. Donald Harvey, PharmD; Anthony F. Shields, MD PhD; Ezra EW. Cohen, MD; Shubham Pant, MD; Rom S. Leidner, MD; Alain Mita, MD; Roger B. Cohen, MD; Bartosz Chmielowski; Mark N. Stein, MD; Siwen Hu-Lieskovan, MD, PhD; Catherine A. Fleener, MS; Ying Ding, PhD; Lei Bao, PhD; Sowmya Chollate, MS; Jolene S. Shorr; Raphael Clynes, MD, PhD; Barbara Hickingbottom, MD | Clinical Trials In Progress | Antibody;Biomarkers;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Immune toxicity;Solid tumors;T cell | |
| 524 | Poster Presentation | A phase 2, multi-arm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors | Vivek Subbiah, MD; Ulka Vaishampayan, MD; Sonam Puri, MD; Lanjia Lin, PhD; Mark Chao, MD, PhD; Giri Ramsingh, MD; Shivaani Kummar, MD; James F. Strauss, MD; Sandip Patel | Clinical Trials In Progress | Antibody;Clinical study;Clinical trial;Solid tumors;Targeted therapy | |
| 525 | Poster Presentation | Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors | Stefan N. Symeonides, MD PhD; Devalingam Mahalingam, MBBChBAO; Young Kwang Chae, MD, MPH, MBA; Emiliano Calvo; Maria Miguel; Hendrik-Tobias Arkenau; Elena Garralda; Vladimir Galvao; Alain Mita, MD; Hariz Hassan, MD; Annette Baumhauer, MD; Timo Völker, PhD; Marie-Cristine Kühnle; Roman Rösemann; Stefan Strobl; Oezlem Tuereci, MD; Ugur Sahin, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Dendritic cell;Solid tumors;T cell;TLR | |
| 526 | Poster Presentation | Removal of Soluble Tumor Necrosis Factors Receptors 1/2 in Patients with Metastatic Solid Tumors Using Immune Apheresis | Ayala Tamir, PhD; Hagit Harati; Nethanel Asher; Ronen Stoff; Shirly Grynberg; Robert Segal; Adam Ostrowski; Lawrence B. Florin; Ronnie Shapira-Frommer; Gal Markel | Clinical Trials In Progress | Biomarkers;Clinical trial;Cytokine;Immune monitoring;Solid tumors | |
| 527 | Poster Presentation | Digital Spatial Profiling of paired tumor biopsies reveals indoleamine 2,3-dioxygenase (IDO)1 as a potential resistance mechanism for a tumor-targeted 4-1BB agonist in patients with solid tumors | Tamara Tanos; Christian Heichinger; Sabine Wilson; Marta Canamero; Mariana Bustamante; Chiahuey Ooi; Irina Klaman; Bruno Gomes, DVM PhD; Maurizio Ceppi | Clinical Trials In Progress | Biomarkers;Bispecifics;Clinical study;Costimulation;Immune contexture;Immune suppression;Myeloid cells;Solid tumors;T cell;Targeted therapy | |
| 528 | Poster Presentation | Correlation of baseline circulating Vg9Vd2 T cell counts and pharmacodynamic activity of ICT01 in cancer patients: preliminary results from EVICTION and a novel patient enrichment strategy | Emmanuel Valentin, PhD; Aude de Gassart, PhD; Patrick Brune; Clément Ghigo; Sophie Agaugué; Daniel Olive; Paul A. Frohna, MD, PhD, PharmD | Clinical Trials In Progress | Antibody;Biomarkers;Immune monitoring;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 529 | Oral Presentation | Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors | Eric Van Cutsem, MD, PhD; Hans Prenen, MD; Brant Delafontaine; Kristen R. Spencer, DO, MPH; Tara C. Mitchell; Howard A. Burris, III, MD; Nuria Kotecki, MD; Rebecca Kristeleit, MD PhD; David J. Pinato, MD, MRes, PhD; Solmaz Sahebjam, MD; Donna M. Graham; Thomas Karasic; Jeannie Daniel; Kevin M. O'Hayer, MD, PhD; Ryan Geschwindt, BS; Sarina A. Piha-Paul, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Solid tumors;T cell;Targeted therapy | |
| 530 | Poster Presentation | A first-in-human phase I study of M6223 (TIGIT inhibitor) as monotherapy or in combination with bintrafusp alfa in patients with metastatic or locally advanced solid unresectable tumors | Geoffrey A. Watson; Meredith McKean, MD; Anthony W. Tolcher, MD; Anja Victor; Sen Zhang; Vadryn Pierre; Emilia Richter; Aung Naing, MD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical trial;Coinhibition;Immune suppression;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 531 | Poster Presentation | A Phase 1b multi-tumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors: results of the triple-negative breast cancer, ovarian cancer, and endometrial cancer cohorts | Ira Winer, mD; Akhila Wimalasingham; Joaquina Baranda; Armando Santoro, MD, PhD; Kristen R. Spencer, DO, MPH; Capucine Baldini, MD; Linda R. Duska, MD; Vivek Subbiah, MD; Sandip Patel; Polina Khrizman; Griet Van Lancker; Lana Andrianova; Sumandeep Atwal; Keerti Sharma; Luis Manso | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Targeted therapy | |
| 532 | Poster Presentation | First-in-Human Phase 1 trial of SRK-181: a latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors (DRAGON trial) | Timothy A. Yap, MD; Minal Barve, MD; Justin Gainor, MD; Bruno Bockorny; Yawen Ju; Shaun Cote, PhD; Sanela Bilic, PharmD, MBA; Lan Liu, MS; Yung Chyung; Michelle Legler; Lu Gan, PhD; Meredith McKean, MD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical trial;Solid tumors | |
| 533 | Poster Presentation | An open label Phase IA/IB study for safety, pharmacokinetics (PK), and efficacy of ONC 392 as a single agent and in combination with Pembrolizumab in advanced solid tumors | Pan Zheng, MD, PhD; Kun He, Ph.D.; Yang Liu, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial | |
| 535 | Poster Presentation | A Phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors | Nehal J. Lakhani, MD; Melissa L. Johnson, MD; Roman Groisberg; Hyunsil Han; Kerry A. Casey; Siyu Li, PhD; Dimitris Skokos, PhD; Frank Seebach, MD; Israel Lowy, MD, PhD; Matthew G. Fury, MD, PhD; Melissa Mathias, MD | Clinical Trials In Progress | Antibody;Bispecifics;Clinical study;Costimulation;Solid tumors | |
| 536 | Poster Presentation | Intratumoral INT230-6 shows a favorable safety profile and early signs of efficacy in advanced soft tissue sarcoma with monotherapy and in combination with Ipilimumab [Intensity IT-01; BMS#CA184-592] | Matthew Ingham, MD; James Hu, MD; Giles F. Whalen, MD; Jacob Thomas, MD; Anthony El-Khoueiry, MD; Diana Hanna, MD; Anthony J. Olszanski, MD, RPh; Christian F. Meyer; Nilofer Azad, MD; Syed Mahmood, MD; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Lilian L. Siu, MD; Albiruni R. Razak | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Solid tumors | |
| 537 | Poster Presentation | OPTIMIZE-1, an open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma | Yago Pico de Coaña, PhD; Yago Pico de Coaña; Karin Enell Smith, PhD, MS; Anette Fält; Maria Flärdh; Peter Ellmark, PhD; Philippe Cassier, MD; Jean-Luc van Laethem, MD; Malin Carlsson | Clinical Trials In Progress | Antibody;Antigen presenting cells;Chemotherapy;Clinical trial;Coinhibition;Costimulation;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Tumor stroma | |
| 538 | Poster Presentation | Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp | Joseph J. Sacco, MD PhD; Richard D. Carvajal; Marcus O. Butler; Alexander N. Shoushtari, MD; Jessica C. Hassel, MD; Alexandra Ikeguchi; Leonel Hernandez-Aya; Paul Nathan, MD, PhD; Omid Hamid, MD; Josep M. Piulats; Matthew Rioth; Douglas B. Johnson, M.D.; Jason J. Luke; Enrique Espinosa; Serge Leyvraz; Chris Holland; Michelle L. McCully; Shaad E. Abedin, MD, FACP; Takami Sato, MD | Clinical Trials In Progress | Bispecifics;Clinical study;Clinical trial;Solid tumors;T cell | |
| 539 | Poster Presentation | Phase 1 study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36γ, for intratumoral (ITu) injection +/- durvalumab in advanced solid tumors and lymphoma | Manish R. Patel, MD; Antonio Jimeno, MD, PhD; Ding Wang, MD; Salomon M. Stemmer; Todd Bauer; Randy F. Sweis, MD; Ravit Geva, MD; Shivaani Kummar, MD; Patrick Reagan, MD; Ruth Perets; Patricia LoRusso; Shilpa Gupta; Sima Zacharek, PhD; Andressa S. Laino; Oleg Milberg; Josh Frederick; Sheryl Chen; Stephanie Pascarella; William Randolph; Praveen Aanur; Lisa Johansen; Khanh T. Do, MD; Robert S. Meehan, MD; Ryan J. Sullivan, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Inflammation;NK/NKT cell;Regulatory T cell (Treg cell);RNA;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 540 | Poster Presentation | Baseline mTOR transcriptional signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors | Chen Zhao, MD; Matthew Mule; Andrew Martins; Iago Pinal Fernandez; Renee N. Donahue, PhD; Jinguo Chen; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD; Andrew L. Mammen; John Tsang; Arun Rajan, MD | Clinical Trials In Progress | Autoimmunity;Checkpoint blockade;Immune toxicity;T cell | |
| 542 | Poster Presentation | Randomized Trial of Tumor Lysate Particle Only Vaccine vs. Tumor Lysate Particle-loaded, Dendritic Cell Vaccine to Prevent Recurrence of Resected Stage III/IV Melanoma: 36-Month Analysis | Elizabth L. Carpenter, MD; Lexy M. Adams, MD, MPH; Robert C. Chick, M.D.; Guy T. Clifton, MD; Timothy J. Vreeland, MD; Franklin A. Valdera, MD; Patrick M. McCarthy, MD; Anne E. O'Shea, MD; Diane F. Hale, MD; Phillip M. Kemp Bohan, MD; Annelies T. Hickeron, MD; John W. Myers, III, MD; Jessica L. Cindass, MD; John Hyngstrom, MD; Adam C. Berger, MD; Jeffrey J. Sussman, MD; James W. Jakub, MD; Montaser Shaheen, MD; Xianzhong Yu, MD; Thomas Wagner, PhD; Mark B. Faries, MD; George E. Peoples, MD | Clinical Trials In Progress | Clinical trial;Dendritic cell;Vaccine | |
| 543 | Poster Presentation | Sensitive quantification and tracking of the active components of a Clonal Neoantigen T cell (cNeT) therapy: From manufacture to peripheral circulation | Samra Turajlic, MD PhD; Mariam Jamal-Hanjani, MD PhD; Andrew Furness, MD PhD; Ruth Plummer; Judith Cave, MD MD(Res); Fiona Thistlethwaite, MD, PhD; Emma Leire, PhD; Jen Middleton, BSc PGCert; Eloise Williams, BSc MSc; Amy Baker; Chloe Maine, BA MA; Michael Epstein; Monica Sassi, PhD; Katy Newton, BSc PhD; Michael Grant, MD BSc PGCert; Matilde Saggese, MD MD(Res); Sergio Quezada, BSc PhD; Martin Forster | Clinical Trials In Progress | Adoptive immunotherapy;Clinical study;Clinical trial;Neoantigens;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 544 | Poster Presentation | DELTA-1: A global, multicenter phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma | Brian Gastman, MD; Omid Hamid, MD; Pippa Corrie; Geoffrey Gibney; Gregory A. Daniels; Bartosz Chmielowski; Sajeve S. Thomas; Evidio Domingo-Musibay; Donald P. Lawrence; Yizhou Jiang; Audrey Kennedy; Jeff Aycock; Ruben Alvarez-Rodriguez; Paul B. Robbins; John Le Gall; Zachary J. Roberts; Robert E. Hawkins, MD, PhD; Amod A. Sarnaik; Brian Gastman | Clinical Trials In Progress | Adoptive immunotherapy;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 545 | Poster Presentation | A Phase 2 Study of Retifanlimab in Patients With Advanced or Metastatic Merkel Cell Carcinoma (MCC) (POD1UM-201) | Giovanni Grignani, MD; Piotr Rutkowski, MD, PhD; Celeste Lebbe, MD, PhD; Natalie Prinzi, MD; Jean-jaques Grob, MD; Enrica Teresa Tanda, MD; Michele Guida, MD; Melissa Burgess, MD; Jennifer Pulini, PharmD; Sadhna Shankar, MD, MPH; Chuan Tian, PhD; Shailender Bhatia, MD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical trial | |
| 546 | Poster Presentation | Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM) | Omid Hamid, MD; Jessica C. Hassel; Alexander N. Shoushtari, MD; Friedegund Meier; Todd Bauer; April Salama, MD; John M. Kirkwood, MD, MD; Paolo A. Ascierto, MD; Paul Lorigan, MD; Cornelia Mauch; Marlana Orloff, MD; Jeff Evans, MD, PhD; Ramakrishna Edukulla; Chris Holland; Shaad E. Abedin, MD, FACP; Renee Mundy; Mark R. Middleton, MD, PhD | Clinical Trials In Progress | Bispecifics;Clinical study;Clinical trial;Solid tumors;T cell | |
| 547 | Poster Presentation | CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma | Andrew M. Haydon, PhD; Muhammad Alamgeer; Daniel Brungs, MBBS; Frances A. Collichio, MD; Nikhil I. Khushalani, MD; Dimitrios Colevas, MD; Danny Rischin, MBBS, MD; Ragini R. Kudchadkar, MD; Wanxing Chai-Ho, MD; Gregory Daniels; Jose Lutzky, MD, FACP; Jenny H. Lee, PhD; Samantha E. Bowyer, MBBCh; Michael R. Migden, MD; Ann W. Silk, MD, MS; Celeste Lebbe, MD, PhD; Jean-jaques Grob, MD; Ignacio J. Melero, Dr., MD, PhD; Piyush Sheladia, MS; Praveen K. Bommareddy, MS, PhD; Shui He, PhD; Claudia Andreu-Vieyra, PhD; Matthew G. Fury, MD, PhD; Andrew Hill, BHB, MBChB, FRACP | Clinical Trials In Progress | B cell;Biomarkers;Checkpoint blockade;Clinical trial;Inflammation;Regulatory T cell (Treg cell);T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 548 | Poster Presentation | Phase 2 study of FLX475 in combination with ipilimumab in advanced melanoma | Rakesh K. Goyal, MD, MRCP; Nicole Nasrah; Dan Johnson; William Y. Ho, MD, PhD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemokine;Clinical study;Clinical trial;Regulatory T cell (Treg cell);Solid tumors;Tumor microenvironment | |
| 549 | Poster Presentation | An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion | Carmen Loquai; Jessica C. Hassel; Patrick Brück; Evelyna Derhovanessian; Katarina Cuk; Verena Lörks; Julian Sikorski; Maike Gold; Daniel Maurus; Doreen Schwarck-Kokarakis; Marion Kästner; Thomas Weisenburger; Ann-Kathrin Eller; Sebastian Attig; Silvana Hempel; Petra Oehm; Tana Omokoko; Lena M. Kranz; Juliane Quinkhardt; Isabel Vogler; Inga Liebig; Stephanie Renken; Melanie Leierer; Verena Müller; Heidrun Mitzel-Rink; Matthias Miederer; Stephan Grabbe; Jochen Utikal; Roland Kaufmann; Ugur Sahin; Özlem Türeci | Clinical Trials In Progress | Clinical study;Clinical trial;RNA;T cell;Tumor antigens;Vaccine | |
| 550 | Poster Presentation | ARTACUS: An open-label, multicenter, phase 1b/2 study of RP1 in solid organ transplant recipients with advanced cutaneous malignancies | Jason J. Luke; Michael R. Migden, MD; Wanxing Chai-Ho, MD; Diana Bolotin, MD, PhD; Trisha M. Wise-Draper, MD, PhD; Andrew Poklepovic, MD; Douglas E. Laux, MD; Meenal K. Kheterpal, MD; Claire F. Verschraegen, MD; Frances A. Collichio, MD; Jose Lutzky, MD, FACP; Gregory Daniels; Katy K. Tsai, MD; Susan Navia, BS, MBA; Henry Castro; Praveen K. Bommareddy, MS, PhD; Andrea Pirzkall, MD; Robert S. Coffin, PhD | Clinical Trials In Progress | Checkpoint blockade;Neoantigens;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 551 | Poster Presentation | Pegasus Skin, a study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers | John PARK, MD; Adyb BAAKILI, MD; Brigitte Demers, MD; Rao Saleem, MD; Alice GOSSELIN; Giovanni Abbadessa, MD; Paolo A. ASCIERTO, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;NK/NKT cell;Solid tumors;T cell | |
Late-Breaking | ||||||
| 951 | Oral Presentation | A Phase 1 first in human study of adenovirally transduced anti-HER2 CAR Macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data | Kim A. Reiss, MD; Yuan Yuan, MD, PhD; Debora Barton, MD; Amy Ronczka, BS; Daniel Cushing, PhD; Michael Klichinsky, PharmD, PhD; Sascha Abramson, PhD; Rehman Qureshi; Thomas Condamine, PhD; Elizabeth C. Dees, MD, MSC; | Clinical Trials In Progress | Adoptive immunotherapy;Antigen presenting cells;Clinical study;Clinical trial;Immune monitoring;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 952 | Poster Presentation | Phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens in the treatment of patients with newly diagnosed glioblastoma | Daniela A. Bota, MD., PhD; David E. Piccioni, MD,PhD; Christopher M. Duma, MD; Renato V. LaRocca, MD; Santosh Kesari, MD, PhD; Mehrdad Abedi, MD; Jose A. Carrillo, MD; Robert D. Aiken, MD; Frank Hsu, MD PhD; Xiaotang Kong, MD, PhD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD; | Clinical Trials In Progress | Clinical trial;Dendritic cell;Stem cell/cancer-initiating cell;Vaccine | |
| 953 | Poster Presentation | Transcriptional Analysis of Leukocytes from COVID Convalescent Donors Reveals Persistent Activation of the Innate and Adaptive Immune System | Mallikarjuna R. Gedda, PhD; Patrick Danaher, PhD; Lipei Saho, PhD; Martin Ongkeko, PhD; Leonard Chen, MD; Mame Thioye Sall, MS; Opal L. Reddy, MD; Christina M. Bailey, MS; Amy Wahba, PhD; Inna Dzekunova, MS; Valeria De Giorgi, PhD; Robert Somerville, PhD; Jin Ping, PhD; Kamille West, MD; Sandhya Panch, MD, MPH; David F. Stroncek, MD; | Clinical Trials In Progress | RNA;COVID and Immunotherapy;Antibody;Clinical study;Gene expression;Granulocyte;Immune monitoring;Inflammation;Regulatory T cell (Treg cell);T cell | |
| 954 | Poster Presentation | Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus | Tereza Brachtlova; Allan Abramovitch, MD; Jonathan Giddens, MD; Peter Incze, MD; Kenneth Jansz, MD; Richard Casey, MD; Victor W. van Beusechem; Wenliang Dong, PhD, MBA; | Clinical Trials In Progress | Clinical study;Clinical trial;Solid tumors;Targeted therapy | |
| 955 | Oral Presentation | CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) | Roger Li, MD; Gary D. Steinberg, MD; Donald Lamm, MD, FACS; Ed M. Uchio, MD; Vignesh Packiam, MD; Ashish M. Kamat, MD; Michael Chisamore, PhD; John McAdory, MHA; Paola Grandi, PhD, MBA; Jee-Hyun Kim, PhD; James Burke, MD; | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Gene expression;Immune monitoring;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 956 | Poster Presentation | Retifanlimab (INCMGA00012) in patients with recurrent MSI-H or dMMR endometrial cancer: Results from the POD1UM-101 study | Dominique Berton, MD; Patricia Pautier, MD; Domenica Lorusso, MD; Christine Gennigens, MD; Laurence Gladieff, MD; Anna Kryzhanivska, MD; Sulabha Ranganathan, PhD; Chuan Tian, PhD; Nawel Bourayou, MD; Ignace Vergote, MD; | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Solid tumors | |
| 957 | Poster Presentation | NKTR-255+cetuximab in patients with solid tumors: Interim safety and efficacy results from the Phase 1b dose-escalation study | Mehmet Altan, MD; Amita Patnaik, MD; Minal A. Barve, MD; Lara A. Dunn, MD; Patrick W. Cobb, MD; Ari Rosenberg, MD; Sunil Sharma, MD; Ammar Sukari, MD; Manish R. Patel, MD; Xiaoli Wang, PhD, MBA; Haijun Ma, PhD; Neha Dixit, PhD; Wildaliz Nieves, PhD; Christie Fanton, PhD; Sue L. Currie, PhD; Zachary Lee, PharmD; Mario Q. Marcondes, MD, PhD; Johnathan Zalevsky, PhD; Mary A. Tagliaferri, MD; Assuntina G. Sacco, MD; | Clinical Trials In Progress | Clinical study;Clinical trial;Cytokine;NK/NK T cell;Solid tumors;T cell;Tumor microenvironment | |
| 958 | Oral Presentation | BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors | Andreas Mackensen, MD; Christian Koenecke, MD; John B. Haanen, MD; Winfried Alsdorf; Alexander Desuki, MD; Eva Wagner-Drouet, MD; Daniel Heudobler, MD; Peter Borchmann, MD; Erol Wiegert; Catrine Schulz; Benjamin Rengstl, MD, PhD; Liane Preussner, MD; Oezlem Tuereci, MD; Ugur Sahin, MD; | Clinical Trials In Progress | RNA;Adoptive immunotherapy;CAR T cells;Clinical trial;Costimulation;Solid tumors;T cell;Tumor antigens;Vaccine | |
| 959 | Oral Presentation | Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial | Martin Wermke; Apostolia-Maria Tsimberidou; Ali Mohamed; Andrea Mayer-Mokler; Arun Satelli; Carsten Reinhardt; Dejka Araujo; Dominik Maurer; George Jr Blumenschein; Harpreet Singh; Jason J. Luke; Kerstin Guenther; Mamta Kalra; Manik Chatterjee; Norbert Hilf; Regina Mendrzyk; Steffen Walter; Stephen Eck; Tobias A.W. Holderried; Toni Weinschenk; Van Morris; Winfried Alsdorf; Cedrik M. Britten; | Clinical Trials In Progress | Adoptive immunotherapy;Clinical study;Clinical trial;Solid tumors;T cell;Targeted therapy | |
| 960 | Poster Presentation | Randomized multicenter study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer | Osama E. Rahma, MD; Mathew HG. Katz, MD; Todd W. Bauer, MD; Brian Wolpin, MD; Chee-Chee H. Stucky, MD; Tanios S. Bekaii-Saab, MD; Rawad Elias, MD; Andressa Dias-Costa, MD; Jonathan Nowak, MD; Lenehan Patrick, MD; Gina R. Petroni; Stephanie Dougan, PhD; Craig L. Slingluff, Jr., MD; | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Radiotherapy;Surgery;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 961 | Poster Presentation | Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy | Iván Márquez Rodas; Philippe Saiag; Luis de la Cruz Merino; Caroline Dutriaux; Juan F. Rodríguez-Moreno; Caroline Robert, MD, PhD; Ana Arance; Eduardo Castañón Álvarez; Pablo Cerezuela-Fuentes; Henry Montaudie, MD, PhD; Miguel Sanmamed, MD, PhD; María González Cao, MD; Julie Charles, MD; María Pilar López Criado; Alfonso Berrocal; Enrique de Miguel; Elisa Funk-Brentano; Sorilla Prey; Roberto M. Huertas; Delvys Rodríguez Abreu; Eva Muñoz Couselo; Juan Martin-Liberal; Javier Sánchez López; Helena Escuin-Ordinas; Marisol Quintero; Sonia Maciá, MD, PhD; Iván Márquez-Rodas, MD, PhD; Marya F. Chaney, PhD; Stephane Dalle; | Clinical Trials In Progress | RNA;Biomarkers;Clinical study;Clinical trial;Dendritic cell;Regulatory T cell (Treg cell);T cell;TLR;Tumor antigens;Tumor microenvironment | |
Presented By:
